Rosuvastatin 5 mg reviews
Pro Research Analysisby 
Searched over 200M research papers
Consensus Meter
Rosuvastatin 5 mg Reviews: Efficacy and Safety
Efficacy of Rosuvastatin 5 mg in Lowering LDL Cholesterol
Rosuvastatin 5 mg has been shown to be effective in significantly reducing low-density lipoprotein cholesterol (LDL-C) levels in various patient populations. In a study involving children and adolescents with familial hypercholesterolemia (HeFH), rosuvastatin 5 mg daily reduced LDL-C by 43% in patients aged 6-9 years, 45% in those aged 10-13 years, and 35% in those aged 14-17 years over a 24-month period. Similarly, in a high-risk Chinese population with hypercholesterolemia, rosuvastatin 5 mg demonstrated a 41.70% reduction in LDL-C, which was comparable to atorvastatin 10 mg.
Comparison with Other Statins
When compared to other statins, rosuvastatin 5 mg has shown superior efficacy. It was found to be more effective at reducing LDL-C and total cholesterol levels compared to atorvastatin 10 mg, simvastatin 20 mg, and pravastatin 20 mg. This superior efficacy allows a greater proportion of patients to reach their LDL-C goals as recommended by various guidelines.
Safety Profile of Rosuvastatin 5 mg
The safety of rosuvastatin 5 mg has been well-documented across multiple studies. In children with familial hypercholesterolemia, the treatment was well tolerated with no adverse effects on growth or sexual maturation. In a study involving hypercholesterolemic adults who were unable to tolerate other statins, rosuvastatin 5 mg was associated with a mean LDL-C reduction of 42% and was well tolerated, with only one patient discontinuing due to myalgia.
In a large multinational clinical trial program involving 16,876 patients, the adverse event profile of rosuvastatin 5-40 mg was similar to that of other statins, with no significant differences in the incidence of muscle, renal, or hepatic toxicity. Additionally, a study comparing the efficacy of rosuvastatin 5 mg and 10 mg in patients with type 2 diabetes mellitus and dyslipidemia found that while both doses were effective, the 10 mg dose was associated with a higher incidence of myalgias.
Conclusion
Rosuvastatin 5 mg is an effective and well-tolerated option for lowering LDL-C in various patient populations, including those who are statin-naive or unable to tolerate other statins. Its superior efficacy compared to other statins and favorable safety profile make it a valuable addition to the treatment options for dyslipidemia.
Sources and full results
Most relevant research papers on this topic